Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Impact of combined resection of pancreas on long-term survival in patients with gastric cancer. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy ...

Trastuzumab with chemotherapy showed numerical improvements in overall survival and progression-free survival in HER2-positive gastric and gastroesophageal junction cancers ... presented at the 2025 ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application ...

Adding evorpacept to treatment with trastuzumab, ramucirumab, and paclitaxel may improve outcomes in HER2-positive gastric/GEJ cancer.

Trastuzumab, tested only as a single agent ... they had measurable lesions (n = 4) or elevated cancer antigen 125 level and non-measurable lesions (n = 3). Three had complete response (6, 7 ...

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.